Skip to search formSkip to main contentSkip to account menu

BIBF 1120

Known as: BIBF-1120, BIBF1120 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

nintedanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing…
6021Background: Radioiodine refractory advanced DTC may benefit from treatment with TKI. Most DTC pts will ultimately progress… 
2016
2016
NiCCC (ENGOT-GYN1): A randomized phase II study of nintedanib (BIBF1120) compared to chemotherapy in patients with recurrent clear-cell carcinoma of the ovary or endometrium.
TPS5603Background: Clear-cell carcinoma (CCC) is an uncommon histotype of ovarian and a rare histotype of endometrial cancer… 
2014
2014
Assessment of the effect of potential antifibrotic compounds on total and αVβ6 integrin‐mediated TGF‐β activation
Transforming growth factor‐β (TGF‐β) plays an important role in the development of tissue fibrosis, and molecules inhibiting this… 
2014
2014
Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
2014
2014
Multi-target angiokinase inhibitors to fight resistance
Tumor progression requires the activation of neovascularization—angiogenesis—a process orchestrated by both tumor and stromal… 
2014
2014
[Exudative onycholysis and acute bacterial paronychia related to BIBF-1120 and paclitaxel: response to topical therapy].
A case of a 50 years-old breast cancer patient treated with weekly paclitaxel and BIBF 1120 is reported herein. At the end of the… 
2014
2014
Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.
7053 Background: Elderly unfit patients with AML have a dismal prognosis. The oral multikinase inhibitor BIBF1120 (nintedanib… 
2013
2013
Abstract 3422: Strategies for molecularly enhanced chemotherapy in endometrial tumors with mutant p53 .
Serous uterine endometrial carcinomas are aggressive type II cancers with a poor outcome and for which new treatment strategies… 
2011
2011
Feasibility of combining EGFR- and VEGF(R)-targeted agents in colorectal cancer.
443 Background: The extensive cross-talk between EGFR and VEGF(R) argues for joint targeting of the two signaling pathways… 
2009
2009
An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.
BACKGROUND To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of BIBF 1120, a triple angiokinase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)